In the specialized field of biochemical research, the dotatate peptide remains a subject of intense fascination for those studying recepto Peptide receptor radionuclide therapy with [177Lu]Lu- r-ligand interactions. As a researcher and enthusiast of peptide synthesis, I have spent significant time examining the molecular architecture of these compounds. At its core, DOTATATE—often referred to as DOTA-(Tyr3)-octreotate—is an eight amino acid long peptide that showcases remarkable precision in binding affinity.
Molecular Composition and Characteristics
When analyzing the structure, it is essential to recognize that DOTATATE is a DOTA-conjugated peptide. The inclusion of the DOTA bifunctional chelator is what allows this molecule to be so versatile in laboratory settings. It acts as a stable cage for various metal ions, which is why it is frequently categorized as a derivatized somatostatin analogue pept Peptide Receptor Radionuclide Therapy with [ 177 Lu] ide.
From my personal experien by L Bodei·2011·Cited by 530—The aim of this prospective phase I-II study was to evaluate the toxicity and efficacy of (177)Lu-DOTATATEin multiple cycles.Read more ce observing these molecular frameworks, the stability provided by the DOTA chelation is superior to many other peptides currently used in experimental protocols. Because it exhibits high affinity for somatostatin receptor subtype 2 (SSTR2), it has become a gold standard for those exploring targeted delivery systems.
Research Applications and Technical Nuance
The utility of this compound extends into various diagnostic and investigative frameworks. For instance, in the context of imaging research, 68Ga-DOTATATE PET/CT parameters are frequently used to noninvasively assess tumor heterogeneity. This allows for a granular view of how specific molecular targets are expressed within a controlled environment.
Furthermore, wh A Clinical Guide to Peptide Receptor Radionuclide en we look at the therapeutic side of the equation—specifically 177Lu-DOTATATE—the data is compelling. Many studies have indicated that 177Lu-DOTATATE demonstrated remarkable tumor shrinkage and tolerability in various experimental models. It is important to note that [177Lu]DOTATATE prolongs progression free survival (PFS) in many observed cases, making it a cornerstone in the study of peptide-based delivery mechanisms.
Why This Peptide Stands Out
Whether I am discussing 177 Lu-DOTATATE therapy or the foundational science of the octreotate sequence, the level of sp 68Ga-DOTATATE PET/CT parameters predict response to ecificity is always the primary draw. The compound functions as a therapeutic compound that is used for treating tumors in clinical research, but for the Neuroendocrine Tumor Diagnosis and Management: 68 Ga bench scientist, its value lies in its predictability.
I have often compared it to other variants like DOTATOC or DOTANOC. While they all share the ability to bind to somatostatin receptors, the specific binding profile of the 177Lu-DOTATATE molecule remains unique. When reviewing documentation on 177Lu-Dotatate peptide receptor radionuclide therapy, one cannot help but notice the meticulous attention to the chelator-peptide bond, which ensures that the radioactivity—or the conjugated cargo—remains securely attached during its transit.
Final Observations
For those looking into the technical specifications of Lutetium 177 (Lu) DOTATATE, it is clear that the field is moving toward higher precision. Whether you are investigating the 177)Lu-DOTATATE cycle efficacy or simply analyzing the structural integrity of this 177Lu]Lu-DOTA-TATE construct, the consistency of the results is what defines its importance in modern biochemistry. Peptide receptor radionuclide therapy with [177Lu]Lu-
As someone who values the precision of synthetic chains, I find the DOTATATE molecule to be one of the most elegant examples of how a small, eight amino acid long peptide can be engineered to achieve such high biological specificity. Whether it is the s progression free survival metrics or the general binding kinetics, this compound continues to be a vital asset in the advancement of peptide-based research.